AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines.
The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Agern Alle 1, Horsholm,zealand 2970,denmark
- Phone
- +45 26394649
- in****@****vac.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- adaptvac.com
- HQ
- Horsholm, Zealand
Adaptvac Questions
Adaptvac's helpline number is +45 26394649
Adaptvac's website is adaptvac.com
Adaptvac's LinkedIn profile is https://dk.linkedin.com/company/adaptvac
Adaptvac has
11 employees.
View email and phone details for 11
employees at Adaptvac.
Adaptvac's industry is
Biotechnology Research
Adaptvac's top competitors are
Enduro,
Minervax Aps,
Bavarian Nordic,
Evaxion A/s,
Var2 Pharmaceuticals,
Expres2ion Biotechnologies,
Cercare Medical,
Stimuliver,
Cell To Cure Aps,
Neumirna Therapeutics.
Adaptvac's support email address is info@adaptvac.com
Adaptvac's categories are Biotechnology Research
Adaptvac's founding year is 2017
